Guneet Janda
About
Research
Publications
2025
Haemostatic Prophylaxis and Colonoscopy Outcomes in Patients With Bleeding Disorders: An Update
Janda G, Shin J, Ashrani A, Sridharan M, Eckerman A, Pruthi R. Haemostatic Prophylaxis and Colonoscopy Outcomes in Patients With Bleeding Disorders: An Update. Haemophilia 2025 PMID: 41403337, DOI: 10.1111/hae.70188.Peer-Reviewed Original ResearchCharacteristics and prognostic factors in adult hemophagocytic lymphohistiocytosis: A large single-institution analysis
Janda G, Parikh S, Alyamany R, Bailen R, Sridharan M, Siddiqui M, Pruthi R, Elliott M, Godby R, Rouse R, Shah S, Padrnos L, Rivera C, Shaikh M, Wysokinska E, Thome S, Jones A, Ticku J, Wolanskyj-Spinner A, Go R. Characteristics and prognostic factors in adult hemophagocytic lymphohistiocytosis: A large single-institution analysis. Blood 2025, 146: 1202-1202. DOI: 10.1182/blood-2025-1202.Peer-Reviewed Original ResearchEpstein-Barr virusElevated blood urea nitrogenHemophagocytic lymphohistiocytosisOverall survivalT cellsBlood urea nitrogenHLH etiologyAdult patientsFollow-upSingle-institution retrospective cohort studyDiffuse large B-cell lymphomaAssociated with Epstein-Barr virusImpaired NK cell activityGraft-vs-host diseaseLarge B-cell lymphomaPost-transplant lymphoproliferative diseaseEpstein-Barr virus-positiveLife-threatening hyperinflammatory syndromeHistory of autoimmune diseaseCohort of adult patientsMultivariate Cox proportional hazards modelAdult-onset hemophagocytic lymphohistiocytosisInterquartile rangeMarkers associated with outcomeAdult hemophagocytic lymphohistiocytosisReal-world outcomes of immune checkpoint inhibitor rechallenge in patients with classical Hodgkin lymphoma
Maiocco G, Nishimura Y, Janda G, Han Y, Durani U, Nowakowski G, Paludo J, Ansell S, Abeykoon J. Real-world outcomes of immune checkpoint inhibitor rechallenge in patients with classical Hodgkin lymphoma. Blood 2025, 146: 5395-5395. DOI: 10.1182/blood-2025-5395.Peer-Reviewed Original ResearchImmune checkpoint inhibitors rechallengeImmune checkpoint inhibitorsProgression-free survivalEvent-free survivalImmune checkpoint inhibitor treatmentRetrospective cohort studyOverall survivalDisease progressionHodgkin lymphomaPSM cohortAssociated with inferior progression-free survivalCycles of ICI therapyImmune checkpoint inhibitor cyclesImmune checkpoint inhibitor discontinuationInferior progression-free survivalInitial ICIAssociated with inferior OSImmune checkpoint inhibitor therapyRetrospective cohort study of patientsSafety dataStage III-IV diseaseOccurrence of disease progressionCohort study of patientsDiagnosis of CHLNon-rechallenge groupRadiomics-based identification of high-risk disease in newly diagnosed multiple myeloma
Janda G, Contreras Guzman E, Howe M, Shreve J, Dasari S, Abdallah N, Gonsalves W, Buadi F, Cook J, Kourelis T, Hayman S, Gertz M, Fonseca R, Dispenzieri A, Rajkumar S, Thorpe M, Kumar S, Binder M. Radiomics-based identification of high-risk disease in newly diagnosed multiple myeloma. Blood 2025, 146: 924-924. DOI: 10.1182/blood-2025-924.Peer-Reviewed Original ResearchTotal tumor volumePresence of high-risk cytogeneticsPretreatment 18F-FDG PET/CT scansHigh-risk cytogeneticsHigh-risk diseaseTumor volumeResponse to therapyMultiple myelomaISS stageOverall survivalRadiomic featuresTumor densityTumor heterogeneityIdentification of high-risk diseaseResponse to first-line therapyExtract quantitative radiomics featuresAssociated with shorter OSExtensive bone marrow involvementPrediction of response to therapyInferior long-term outcomesPredictive of overall survivalHigh riskPET/CT scans of patientsCross-sectional imaging studiesAdvanced ISS stageOutcomes of immune checkpoint inhibitor rechallenge in relapsed/refractory Hodgkin lymphoma
Nishimura Y, Han Y, Toumeh N, Janda G, Fujiwara Y, Durani U, Nowakowski G, Paludo J, Ansell S, Abeykoon J. Outcomes of immune checkpoint inhibitor rechallenge in relapsed/refractory Hodgkin lymphoma. Blood Neoplasia 2025, 2: 100134. PMID: 40809195, PMCID: PMC12346057, DOI: 10.1016/j.bneo.2025.100134.Peer-Reviewed Original ResearchImmune checkpoint inhibitorsProgression-free survivalImmune checkpoint inhibitors rechallengeOverall response rateHodgkin lymphomaAdverse eventsICI rechallengeComplete responseResponse rateMedian progression-free survivalImmune-related adverse eventsRelapsed/Refractory Hodgkin LymphomaPooled response rateConfidence intervalsClassical HLICI therapyR/R HLCheckpoint inhibitorsAny-gradeSystematic literature searchCR ratePatient selectionSafety profileRechallengePreferred Reporting ItemsUtilization of tumor-informed ctDNA to de-escalate treatment or monitoring in metastatic breast cancer exceptional responders.
Janda G, Goetz M, Haddad T, Peethambaram P, Leon-Ferre R, Calkins H, Scott N, Rodriguez A, Liu M, Giridhar K. Utilization of tumor-informed ctDNA to de-escalate treatment or monitoring in metastatic breast cancer exceptional responders. Journal Of Clinical Oncology 2025, 43: e13042-e13042. DOI: 10.1200/jco.2025.43.16_suppl.e13042.Peer-Reviewed Original ResearchMetastatic breast cancerSystemic therapyCtDNA testingContinuous endocrine therapyRadiographic remissionRestaging scansEndocrine therapyExceptional respondersER+/HER2- metastatic breast cancerCohort of ptsDiscontinued systemic therapySystemic therapy optionsTreatment de-escalationBreast cancer characteristicsMedian Follow-UpDe-escalate treatmentTreating medical oncologistMetastatic breast cancer diagnosisIRB-approved protocolIncreased imaging frequencyConventional treatment paradigmsProgression of diseaseCtDNA-positiveHER2+Median durationResearch Derived From Medicare’s Coverage With Evidence Development Program
Janda G, Moneer O, Mooghali M, Ramachandran R, Wallach J, Dhruva S, Ross J. Research Derived From Medicare’s Coverage With Evidence Development Program. JAMA Network Open 2025, 8: e255077. PMID: 40232723, PMCID: PMC12000966, DOI: 10.1001/jamanetworkopen.2025.5077.Peer-Reviewed Original ResearchCharacterization of studies considered and required under Medicare’s coverage with evidence development program
Mooghali M, Moneer O, Janda G, Ross J, Dhruva S, Ramachandran R. Characterization of studies considered and required under Medicare’s coverage with evidence development program. Clinical Trials 2025, 22: 619-625. PMID: 39921418, DOI: 10.1177/17407745251313979.Peer-Reviewed Original ResearchCenters for MedicareMedicare beneficiariesIdentified original research articlesMedicare coverageClinical trial studyEvidence developmentTrial studyQuality of evidenceCoverage decisionsPrimary endpointClinical outcome measuresEvidence of benefitRandomized study designClinical studiesOriginal research articlesDecision MemoMedicaid ServicesOutcome measuresNational Coverage DeterminationMedicareMulti-arm designStudy designDissemination of studiesGoogle ScholarUS patientsAlterations in Gut Microbiome-Host Relationships After Immune Perturbation in Patients With Multiple Sclerosis
Gupta V, Janda G, Pump H, Lele N, Cruz I, Cohen I, Ruff W, Hafler D, Sung J, Longbrake E. Alterations in Gut Microbiome-Host Relationships After Immune Perturbation in Patients With Multiple Sclerosis. Neurology Neuroimmunology & Neuroinflammation 2025, 12: e200355. PMID: 39819054, PMCID: PMC11741292, DOI: 10.1212/nxi.0000000000200355.Peer-Reviewed Original ResearchConceptsAmplicon sequence variantsIgA-coatedGut microbiomeBacterial fractionRRNA gene amplicon sequencingLong-read sequencingGut microbial symbiontsGene amplicon sequencingMultiple sclerosisStool samplesProportion of bacteriaB cellsHost-microbial interfaceAnti-CD20 monoclonal antibody treatmentDiagnosing MSMicrobial symbiontsIgA-secreting B cellsTaxonomic resolutionSequence variantsAmplicon sequencingB-cell depletionFecal microbiotaMonths of treatmentMonoclonal antibody treatmentDevelopment of autoimmunityAssessing Medicare’s Coverage With Evidence Development Program
Mooghali M, Moneer O, Janda G, Dhruva S, Ross J, Ramachandran R. Assessing Medicare’s Coverage With Evidence Development Program. Health Affairs 2025, 44: 32-39. PMID: 39761464, DOI: 10.1377/hlthaff.2024.00814.Peer-Reviewed Original Research